6. Further information
British National Formulary—available online
Martindale: the complete drug reference—available online
NICE. Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care – clinical guideline 82 (issued March 2009)
Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567–620
Information from MHRA
Note. References to older MHRA1 advice is included for background only; the information will have been incorporated into summaries of product characteristics and some will have been superseded.
Source | Article title | Comment |
|---|---|---|
Drug Safety Update September 2011 | Risk of extrapyramidal effects and withdrawal effects in newborns born to mothers on antipsychotics during the third trimester | |
Drug Safety Update April 2011 | ||
MHRA website March 2010 | Uses of antipsychotics, mechanism of action, side-effects and use in elderly people with dementia | |
Drug Safety Update June 2009 | Before and during treatment with antipsychotics, risk factors for venous thromboembolism should be identified and addressed | |
Drug Safety Update March 2009 | Antipsychotics may increase risk of stroke and slightly increase risk of early death in the elderly | |
Pharmacovigilance Working Party assessment report | Basis for the introduction of warning on cardiovascular adverse events into summaries of product characteristics |
- Medicines and Healthcare products Regulatory Agency, the government body which regulates many aspects of the testing, manufacture, supply, and use of medicines and medical devices↩